学会・セミナー 無細胞生命科学部門




講演者の小澤 彰彦先生は,遠藤研(旧無細胞生命科学工学研究センター)で学位取得後,FivePrime Therapeutics, Inc, Louisiana State University, University of Maryland, Baltimore を経て,現在フロリダのTorrey Pines Institute for Molecular Studiesで研究を続けております。現在の研究分野は,翻訳後修飾による分泌タンパク質の活性調節などです。


◆講 師:小澤 彰 彦 先生
(Torrey Pines Institute for Molecular Studies, Senior Scientist)
◆タイトルAugurin, a tumor suppressor candidate
◆日 時:平成25年12月26日(木) 午後5時から
◆場 所:ベンチャー・ビジネス・ラボラトリー4階会議室
【要 旨】 ※講演は日本語で行います
Augurin, also called esophageal cancer related gene 4 (ECRG4), is a secretory molecule highly conserved among all vertebrates. Augurin has been reported to function as a tumor suppressor gene, as a neuropeptide and as a differentiation factor. Our current study has focused on how this molecule acts as a tumor suppressor. Just as other tumor suppressor genes, the promoter of augurin gene is hypermethylated in many cancer cell lines. These data imply that the expression of proaugurin or a proaugurin-derived peptide functions as a tumor suppressor. So far, the endogenous forms of proaugurin-derived peptides, which can act in tumor suppression, have yet to be determined. Our report has shown that a major proaugurin-derived peptide is generated by the action of furin, a member of the proprotein convertase family, and that proaugurin undergoes tyrosine sulfation. The goals of this project are 1) to understand the posttranslational modifications required of augurin to act as a tumor suppressor; and 2) to clarify the pathogenical correspondence between the expression of augurin and the generation of glioblastoma.
In this talk, I will walk you through this project with my previous and recent data, then I will conclude with highlighting the future direction of this study.